News >

ASCT Remains Significant Upfront Option in AL Amyloidosis

Jason Harris
Published: Wednesday, Apr 11, 2018

Morie A. Gertz, MD

Morie A. Gertz, MD
In a 20-year observational study, investigators at Mayo Clinic Rochester found that autologous stem-cell transplantation (ASCT) improved overall survival (OS) and reduced treatment-related mortality in patients with immunoglobulin light chain (AL) amyloidosis.

 Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time [published online March 20, 2018]. J Clin Oncol. 76.9554.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication